TY - JOUR
T1 - Clinicopathological significance of circadian rhythm-related gene expression levels in patients with epithelial ovarian cancer
AU - Tokunaga, Hideki
AU - Takebayashi, Yuji
AU - Utsunomiya, Hiroki
AU - Akahira, Jun Ichi
AU - Higashimoto, Masashi
AU - Mashiko, Miyuki
AU - Ito, Kiyoshi
AU - Niikura, Hitoshi
AU - Takenoshita, Sei Ichi
AU - Yaegashi, Nobuo
PY - 2008
Y1 - 2008
N2 - Objective. Recent studies implicate circadian genes in the regulation of cell cycle, apoptosis, and cell proliferation at a molecular level. These genesey affect cancer incidence, prognosis, and chemosensitivity. In this study, we measured the expression levels of clock genes and correlated their expression levels with clinicopathological parameters in epithelial ovarian cancer. Methods. The expression levels of core clock genes, per1, per2, per3, cry1, cry2, Bmal1, clock, and CKIε were quantified by real-time quantitative Reverse transcription-polymerase chain reaction in 83 ovarian cancer tissues and 11 normal ovarian tissues. Results. The expression levels of per1, per2, cry2, clock, CKIε in ovarian cancers were significantly lower than those in normal ovaries. In contrast, cry1 expression was highest among the eight examined clock genes, followed by per3 and Bmal1. Cry1 expression was much higher in cancer than that in normal ovaries. Localized circadian gene expression was determined in cancer cells by in situ hybridization analysis. Cry1 expression was significantly reduced in mucinous and grade 3 tumors. Bmal1 expression was also significantly reduced in mucinous adenocarcinomas as compared to other histologies. In a multivariate analysis, the combination of low cry1 expression and low Bmal1 expression was an independent prognostic factor, as well as stage and histological subtype. Conclusions. The antiphase expression of cry1 and Bmal1 may be preserved in ovarian cancers. The combination of cry1 and Bmal1 expression might become a possible prognostic marker in epithelial ovarian cancer.
AB - Objective. Recent studies implicate circadian genes in the regulation of cell cycle, apoptosis, and cell proliferation at a molecular level. These genesey affect cancer incidence, prognosis, and chemosensitivity. In this study, we measured the expression levels of clock genes and correlated their expression levels with clinicopathological parameters in epithelial ovarian cancer. Methods. The expression levels of core clock genes, per1, per2, per3, cry1, cry2, Bmal1, clock, and CKIε were quantified by real-time quantitative Reverse transcription-polymerase chain reaction in 83 ovarian cancer tissues and 11 normal ovarian tissues. Results. The expression levels of per1, per2, cry2, clock, CKIε in ovarian cancers were significantly lower than those in normal ovaries. In contrast, cry1 expression was highest among the eight examined clock genes, followed by per3 and Bmal1. Cry1 expression was much higher in cancer than that in normal ovaries. Localized circadian gene expression was determined in cancer cells by in situ hybridization analysis. Cry1 expression was significantly reduced in mucinous and grade 3 tumors. Bmal1 expression was also significantly reduced in mucinous adenocarcinomas as compared to other histologies. In a multivariate analysis, the combination of low cry1 expression and low Bmal1 expression was an independent prognostic factor, as well as stage and histological subtype. Conclusions. The antiphase expression of cry1 and Bmal1 may be preserved in ovarian cancers. The combination of cry1 and Bmal1 expression might become a possible prognostic marker in epithelial ovarian cancer.
KW - Circadian gene
KW - Ovarian cancer
UR - http://www.scopus.com/inward/record.url?scp=53849124685&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=53849124685&partnerID=8YFLogxK
U2 - 10.1080/00016340802348286
DO - 10.1080/00016340802348286
M3 - Article
C2 - 18720043
AN - SCOPUS:53849124685
SN - 0001-6349
VL - 87
SP - 1060
EP - 1070
JO - Acta Obstetricia et Gynecologica Scandinavica
JF - Acta Obstetricia et Gynecologica Scandinavica
IS - 10
ER -